SNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. The chart setup is still bearish (SMA_200 > SMA_20 > SMA_5 with MACD slightly negative), options positioning is decisively put-heavy (bearish/defensive sentiment), and the Street narrative has turned more cautious with multiple downgrades tied to pipeline/replacement-risk concerns post-Dupixent LOE. While Rezurock’s EMA recommendation is a positive catalyst, it’s not strong enough to offset the current negative trend + sentiment for an impatient buyer looking to enter immediately.
Intellectia Proprietary Trading Signals
Trend/structure remains weak. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), implying the longer-term downtrend is still intact. Momentum is not confirming a rebound yet: MACD histogram is slightly below zero (-0.00244) and only contracting modestly, suggesting downside momentum is easing but not flipping bullish. RSI_6 ~51.9 is neutral (no oversold bounce signal). Near-term levels: pivot 46.578 is immediate support; below that S1 45.571 then S2 44.949. Overhead resistance sits at R1 47.584 and R2 48.206—price (46.94) is closer to resistance than deep value support, so risk/reward for a fresh impatient entry is not compelling. Pattern-based forecast in your data also tilts negative over 1 week to 1 month (-2.29% / -3.88%).
EMA recommended conditional approval for Rezurock for chronic graft-versus-host disease (regulatory catalyst that can support future revenue growth).
Dupixent sales growth remains strong (+32.2% in the reported quarter), showing continued execution in a key franchise.
Hedge fund flow signal is positive: “Hedge Funds are Buying,” with buying amount up ~231.75% over the last quarter (supportive demand indicator).
Earnings/revenue quality: Q4 sales rose ~7% YoY but were below expectations (headline miss tends to cap near-term upside).
Concentration/LOE narrative: multiple analysts cite pipeline replacement risk and challenges post-Dupixent loss of exclusivity, which is weighing on sentiment.
Vaccine sales decline (a drag within the quarter).
Options positioning is put-dominant (often associated with bearish expectations or heavy hedging).
Latest quarter referenced in the news: Q4 (2025). Revenue/sales grew ~7% year-over-year to about $13.159B but missed expectations. Adjusted EPS reported at €1.53. Growth was notably driven by Dupixent (+32.2%), while vaccine sales declined. Overall: positive growth in the core growth driver, but mixed segment performance and an expectation miss reduce near-term momentum.
Recent trend is clearly deteriorating: multiple downgrades/neutral initiations and price target cuts in Jan 2026 (UBS cut PT to EUR 88 from EUR 105 and downgraded to Neutral; Citi initiated Neutral with EUR 85; Barclays downgraded to Equal Weight; Guggenheim downgraded to Neutral in Dec). While Deutsche Bank/HSBC still show Buy ratings with higher targets, the dominant near-term takeaway from Wall Street is: (Pros) durable near-term Dupixent strength and potential upside from approvals like Rezurock; (Cons) insufficient visible pipeline catalysts over the next ~12 months and strategic/pipeline replacement risk post-LOE, plus potentially reduced buyback capacity.
